Literature DB >> 17923114

VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice.

Chengyun Zheng1, Mattias K Sköld, Jian Li, Inger Nennesmo, Bengt Fadeel, Jan-Inge Henter.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting from motor neuron loss in the spinal cord and brain stem. In the present study, we found that systemic administration of recombinant vascular endothelial growth factor (VEGF) significantly diminished astrogliosis and increased the number of neuromuscular junctions in a Cu/Zn superoxide dismutase (SOD1) transgenic mouse model of ALS. Our results thus demonstrate a novel regulatory role of VEGF on astrocytes and are suggestive of protective effects of VEGF both in the peripheral and central nervous system in the SOD1 transgenic mouse model. These findings warrant further evaluation of the mechanism(s) of regulatory effects of VEGF on neuronal and non-neuronal cells, and the relation of these events to motor neuron degeneration and the onset and progression of ALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923114     DOI: 10.1016/j.bbrc.2007.09.088

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

Review 2.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

Review 3.  The "dying-back" phenomenon of motor neurons in ALS.

Authors:  Michal Dadon-Nachum; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2010-11-07       Impact factor: 3.444

4.  Spinal vascular endothelial growth factor induces phrenic motor facilitation via extracellular signal-regulated kinase and Akt signaling.

Authors:  Erica A Dale-Nagle; Irawan Satriotomo; Gordon S Mitchell
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

Review 5.  Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes.

Authors:  Marcelo R Vargas; Jeffrey A Johnson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

6.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

7.  Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration.

Authors:  J Simon Lunn; Stacey A Sakowski; Bhumsoo Kim; Andrew A Rosenberg; Eva L Feldman
Journal:  Dev Neurobiol       Date:  2009-11       Impact factor: 3.964

8.  Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats.

Authors:  Maria Nikodemova; Alissa L Small; Stephanie M C Smith; Gordon S Mitchell; Jyoti J Watters
Journal:  Neurobiol Dis       Date:  2013-11-19       Impact factor: 5.996

9.  Astrocyte-like cells derived from human oral mucosa stem cells provide neuroprotection in vitro and in vivo.

Authors:  Javier Ganz; Ina Arie; Tali Ben-Zur; Michal Dadon-Nachum; Sammy Pour; Shareef Araidy; Sandu Pitaru; Daniel Offen
Journal:  Stem Cells Transl Med       Date:  2014-01-29       Impact factor: 6.940

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.